Additionally, the analysis considered the companies’ product portfolios, emphasizing their key products and innovations within the medical device sector. Geographical presence and expansion strategies, particularly in emerging markets like Southeast Asia, were also assessed to understand the companies’ global footprint and growth initiatives. Cross-referencing these findings with industry rankings and expert opinions ensured a comprehensive and accurate identification of the top players in the medical device industry.

Global Top 10 Medical Device Companies

1. Medtronic

• Headquarters: Dublin, Ireland
• Revenue (2023): $31.69 billion (Medtronic Annual Report 2023)
• Key Products: Cardiac and vascular devices, surgical technologies, diabetes management
• Strategies:
  • Innovation: Heavy investment in R&D, focusing on advanced medical technologies.
  • Acquisitions: Frequent strategic acquisitions to expand product portfolio and market presence.
  • Global Expansion: Targeting emerging markets for growth, particularly in Asia and Latin America.
• Expansion Activities to Southeast Asia:
  • Market Penetration: Medtronic has been focusing on increasing its market share in Southeast Asia through partnerships and collaborations with local healthcare providers.
  • Localization: Adapting products to meet local healthcare needs and regulatory requirements.
  • Training Programs: Establishing training centers for healthcare professionals to enhance the adoption of their devices.
• Recent Moves:
  • Expanded its presence in markets like Singapore, Malaysia, and Indonesia.
    • Singapore Medical Devices Industry Research Report 2024-2033
    • Indonesia Medical Devices Industry Research Report 2024-2033
  • Launched several initiatives to improve access to advanced medical technologies in the region.

2. Johnson & Johnson (J&J)

• Headquarters: New Brunswick, New Jersey, USA
• Revenue (2023): $25.96 billion (medical devices segment, Johnson & Johnson Annual Report 2023)
• Key Products: Orthopedics, surgery, cardiovascular, diabetes care
• Strategies:
  • Diversification: Strong portfolio across pharmaceuticals, medical devices, and consumer health products.
  • Innovation and R&D: Significant investment in research and development.
  • Strategic Partnerships: Collaborating with startups and other companies to foster innovation.

3. Siemens Healthineers

• Headquarters: Erlangen, Germany
• Revenue (2023): $22.73 billion
• Key Products: Imaging systems, diagnostic equipment, advanced therapies
• Expansion Activities to Southeast Asia:
  • Strategic Investments: Investing in local manufacturing facilities and R&D centers.
  • Collaborations: Partnering with local governments and healthcare organizations to improve healthcare infrastructure.
  • Market Access: Utilizing its extensive global network to ensure efficient distribution and accessibility of products.
• Recent Moves:
  • Increased focus on the ASEAN region, particularly in countries like Vietnam and Thailand.
    • Vietnam Medical Devices Industry Research Report 2024-2033
    • Collaborated with local institutions to enhance healthcare education and training.

4. GE Healthcare

• Headquarters: Chicago, Illinois, USA
• Revenue (2023): $18.01 billion
• Key Products: Imaging, ultrasound, life care solutions, biopharma
• Expansion Activities to Southeast Asia:
  • Innovation Hubs: Setting up innovation hubs and R&D centers to develop solutions tailored to the region’s needs.
  • Training Programs: Establishing education and training programs for healthcare professionals.
  • Public-Private Partnerships: Engaging in public-private partnerships to enhance healthcare infrastructure.
• Recent Moves:
  • Increased presence in Indonesia and Vietnam, focusing on improving healthcare access and affordability.
    • Vietnam Medical Devices Industry Research Report 2024-2033
    • Indonesia Medical Devices Industry Research Report 2024-2033
  • Launched several community health initiatives to address local healthcare challenges.

5. Abbott Laboratories

• Headquarters: Abbott Park, Illinois, USA
• Revenue (2023): $17.64 billion (medical devices segment)
• Key Products: Diagnostics, cardiovascular, neuromodulation, diabetes care
• Expansion Activities to Southeast Asia:
  • Local Manufacturing: Establishing manufacturing plants in the region to cater to local demand.
  • Healthcare Access: Working on initiatives to improve healthcare access in rural and underserved areas.
  • Product Customization: Adapting products to meet the specific healthcare needs of the local population.
• Recent Moves:
  • Increased investment in Malaysia and Indonesia, focusing on nutrition and diagnostics.
    • Indonesia Medical Devices Industry Research Report 2024-2033
  • Launched community health programs to address chronic disease management.

6. Philips Healthcare

• Headquarters: Amsterdam, Netherlands
• Revenue (2023): $17.36 billion
• Key Products: Imaging systems, patient care, healthcare informatics
• Expansion Activities to Southeast Asia:
  • Digital Health: Promoting connected care and telehealth solutions to bridge healthcare gaps in remote areas.
  • Sustainability: Emphasizing sustainable healthcare solutions and practices.
  • Local Collaboration: Collaborating with local healthcare providers to deliver customized healthcare solutions.
• Recent Moves:
  • Expanded operations in countries like Thailand and the Philippines.
  • Launched initiatives to support maternal and child health through digital solutions.

7. Stryker Corporation

• Headquarters: Kalamazoo, Michigan, USA
• Revenue (2023): $17.12 billion
• Key Products: Orthopedics, medical and surgical equipment, neurotechnology
• Strategies:
  • Acquisitions: Frequent acquisitions to expand product lines.
  • Innovation: Investing in R&D to develop new and advanced products.
  • Market Expansion: Growing presence in international markets.

8. Boston Scientific

• Headquarters: Marlborough, Massachusetts, USA
• Revenue (2023): $12.87 billion
• Key Products: Cardiovascular, urology, endoscopy, neuromodulation
• Strategies:
  • Product Diversification: Broad product portfolio in minimally invasive therapies.
  • Innovation: High investment in R&D for breakthrough technologies.
  • Geographic Expansion: Increasing presence in high-growth markets.

9. Becton Dickinson (BD)

• Headquarters: Franklin Lakes, New Jersey, USA
• Revenue (2023): $11.66 billion
• Key Products: Medical supplies, diagnostic equipment, biosciences
• Strategies:
  • Operational Efficiency: Streamlining operations and reducing costs.
  • Innovation: Focusing on product development and improving existing products.
  • M&A Activities: Strategic mergers and acquisitions to bolster portfolio.

10. Zimmer Biomet

• Headquarters: Warsaw, Indiana, USA
• Revenue (2023): $7.74 billion
• Key Products: Orthopedic implants, surgical products, biologics
• Strategies:
  • Product Innovation: Investing in new technologies and products.
  • Global Expansion: Increasing market share in international markets.
  • Operational Efficiency: Improving manufacturing and supply chain operations.

The post 2024 Global Top 10 Medical Device Companies & Expanding to Southeast Asia Market first appeared on CRI Report.

Vitamins are fundamental supplements that are needed to create and work the body typically. They are additionally fundamental for solid digestion. The inadequacy of vitamins can cause issues, though the resupply of these supplements can lighten insufficiency side effects. The accomplished vitamins incorporate A, B, C, D, E, and K. Thiamin (B1), riboflavin (B2), niacin (B3), pantothenic corrosive (B5), pyridoxal (B6), cobalamin (B12), biotin, and folate/folic corrosive are some notable kinds of nutrient B.

Overall, the vitamins market is expected to continue to grow in the coming years as consumers become more health-conscious and seek out products that support their overall well-being.

The vitamins market is expected to continue its growth trajectory in the coming years.

The global vitamins market is projected to register a CAGR of 5.70% and reach a value of USD10,079.92 million by 2028.

Global Vitamins Market—Forecast till 2028

There are a few factors emphatically or contrarily influencing the global market growth. Vitamins are fundamental micronutrients that are needed to work digestion appropriately.

In addition, there is a growing trend towards personalized nutrition and the use of vitamins and supplements to address specific health concerns. This has led to the development of innovative products and delivery formats, such as gummies and chews, that are more appealing to consumers.

However, the vitamins market is also facing some challenges, such as regulatory issues and the growing popularity of natural and organic products. In addition, there is increasing competition from other categories such as functional foods and beverages.

Vitamins can be regular or manufactured. Notwithstanding, it is extended that the demand for normal vitamins is relied upon to increment during the COVID-19 pandemic and for the following coming years. The expanding utilization of vitamins in the food business across application regions like pastry shops and candy stores, dairy and frozen sweets, comfort food, and beverages is relied upon to increment as certain vitamins are utilized as a food added substance.

Regional Analysis

Geographically, the global vitamins market has been spread across North America, Europe, Asia-Pacific, and the rest of the world. Asia-Pacific represented the biggest piece of the pie of 32.46% in 2020 and is likewise expected to register the largest development rate from 2021 to 2028. Europe was the second-biggest market in 2020 and is projected to show a CAGR of 5.08% during the survey time frame.

The Asia-Pacific vitamins market represented the largest portion of the worldwide market in 2020. China exhibits the major nation-level market in the locale, representing the biggest portion of the overall industry during the survey time frame. Vitamins are utilized as a fixing in a few utilitarian foods. The utilization of supplementary foods is ascending across the emerging economies of Asia-Pacific inferable from the expanding per-capita expenditure, and urbanization.

Global Vitam D Market

Vitamin D is a crucial nutrient that helps the body absorb calcium, maintain healthy bones and teeth, and support immune function. It can be obtained through diet, sunlight exposure, and supplements. The vitamin D market includes products such as supplements, fortified foods, and pharmaceuticals.

The COVID-19 pandemic has contributed to the growth of the vitamin D market, as studies have suggested that vitamin D supplementation may help improve immune function and reduce the risk of respiratory infections. However, the extent to which this has impacted the market is unclear and may require further analysis.

The global vitamin D market covers North America, Asia-Pacific, Latin America, Europe, and the Middle East and Africa regions.

global vitamin D market is expected to witness a growth trend at a CAGR of 7.51% during the forecast period 2023-2030.

GLOBAL VITAMIN D MARKET 2023-2030

North America Vitamin D Market

North America Vitamin D market is foreseen to garner a compound annual growth rate of 7.77% over the forecasting years from 2023 to 2030. 

NORTH AMERICA VITAMIN D MARKET 2023-2030

Asia-Pacific Vitamin D Market

Asia-Pacific vitamin D market is set to observe growth at a CAGR of 7.71% during the forecasted years of 2023-2030.

ASIA-PACIFIC VITAMIN D MARKET 2023-2030

Latin America Vitamin D Market

Latin America vitamin D market is projected to progress with a compound annual growth rate of 7.23% during the forecast period 2023-2030. 

LATIN AMERICA VITAMIN D MARKET 2023-2030

Europe Vitamin D Market

Europe vitamin D market will showcase a compound annual growth rate of 7.28% in value during 2023-2030.

EUROPE VITAMIN D MARKET 2023-2030

Middle East and Africa Vitamin D Market

Middle East and Africa vitamin D market will advance in value at a compound annual growth rate of 7.12% during the forecast years 2023-2030.

MIDDLE EAST AND AFRICA VITAMIN D MARKET 2023-2030

Factors that may influence the vitamin D market include changing dietary patterns, increasing health awareness, and technological advancements in manufacturing and formulation. However, regulatory constraints and high costs associated with clinical trials and research may also pose challenges for companies operating in this space.

China’s Vitamin E Export

China is one of the major producers and exporters of vitamin E worldwide. According to Research Report on China’s Vitamin E Export 2023-2032, China’s vitamin E export volume generally shows fluctuating changes in 2018-2021. In 2019, China’s vitamin E export volume decreases from 75,000 tons to 69,300 tons, down 7.63% y-o-y. In 2020-2021, China’s vitamin E export volume increases continuously. In 2021, China exports 91,300 tons of vitamin E, up 30.92%.

In 2022, China’s vitamin E exports declined due to the COVID-19 outbreak. From January to October 2022, China exported 63,100 tons of vitamin E, down 14.92% year-on-year.

In recent years, China has become a major global producer and exporter of vitamin E. CRI expects the global vitamin E market to gradually expand in size from 2023-2032, so China’s vitamin E exports are expected to continue to grow.

China’s Vitamin C Export

China is one of the world’s major vitamin C producers and exporters. According to Research Report on China’s Vitamin C Export 2023-2032, in 2021, China exported 197,600 tons of vitamin C, down 4.57% year-on-year, with an export value of US$942 million, up 24.87% year-on-year. From January to October 2022, China exported 161,400 tons of vitamin C, up 4.19% year-on-year, with an export value of US$695 million, down 5.77% year-on-year.

In 2021, China exported vitamin C to more than 160 countries and regions around the world. CRI analysis shows that by export volume, the U.S., Germany, the Netherlands, Japan, Brazil, Indonesia, Poland, India, South Korea and Vietnam are the main export destinations for vitamin C from China. 

In recent years, China has become a major global producer and exporter of vitamin C. CRI expects the global vitamin C vegetarian market size to continue to grow from 2023-2032, helping to boost China’s vitamin export volume.

The post Vitamin D and Other Vitamins Market Growth Forecast in 2023 first appeared on CRI Report.

• Vietnam Medical Devices Industry Research Report 2024-2033
• Singapore Medical Devices Industry Research Report 2024-2033
• Indonesia Medical Devices Industry Research Report 2024-2033

Industry Overview

Medical Equipment Companies in China develop fast in recent 3 years for the covid-19 epidemic.

With the emergence of high-quality medical devices and the continuous innovation, the pattern of China’s medical industry is being reshaped.

Relevant data show that as of 2020,  China’s medical equipment market size is about 734.1 billion yuan, an increase of 18.3% year-on-year, nearly four times the growth rate of global medical devices, and has become the world’s second largest medical device market after the United States.

2021 China’s Top 10 Medical Equipment Companies in China

Related Report: Global Top 10 Medical Device Technologies Market Analysis and Forecast Report 2030

Source: Internet

2024 Global Top 10 Medical Device Companies & Expanding to Southeast Asia Market

China’s Medical Device Industry Outlook

Overall, the development of Medical Equipment Companies in China has great potential, and the Covid-19 epidemic has become a “combustion agent” to promote its rapid development.

After the epidemic, the market demand for medical devices and consumables such as masks, nucleic acid detection kits, and ECMO surged. The market size exceeded 1 trillion yuan, and the growth rate was as high as 40% in 2020.

In addition, Medical Equipment Companies in China have made frequent moves in financing mergers and acquisitions since this year. In the first half of 2021, the domestic medical device financing heat reached a record high, with more than 217 financing events, a year-on-year increase of 50.73%, and 105 financing events of 100 million yuan.

From the market point of view, the medical device segment is relatively abroad, covering from in vitro diagnosis, minimally invasive to large medical equipment. This industry needs continuous R&D accumulation with high barriers. Only Medical Equipment Companies in China with new technologies can make it possible to quickly capture the market share.

Related Report: Global Medical Device Accessories Market Research Report- Forecast to 2023 

Therefore, related companies will seize high-potential market segments through mergers and acquisitions as a solution.

Mergers and acquisitions are not the only road to Rome. In recent years, Internet giants such as Tencent, Ali, and Meituan have entered the medical device industry, and Luckin and Gree have also come across the industry.

Therefore, in the face of the complex competitive environment, there are still some enterprises as the core competitiveness of enterprise development by investing in scientific research costs and improving their own hard power.

Only by emphasizing the innovation of varieties and the exclusivity of the market, will the enterprise form an increasingly deep moat in the corresponding field and is expected to become the industry leader.

Driving Factors

The aging population, technological breakthroughs in the medical industry, consumption upgrades, and the public’s emphasis on health are all driving the development of medical devices in the segmented field.

The post 2022 Top Medical Equipment Companies in China first appeared on CRI Report.

According to the market intelligence report by Our Research Team titled Narcolepsy Therapeutics Market – A Global and Regional Analysis, the market was valued at $915.2 million in 2021 and is anticipated to reach $4,912.3 million by 2032, growing at a CAGR of 15.93% during the forecast period 2022-2032.

In the comprehensive study of the global narcolepsy therapeutics market, Our Research Team extensively covers the following:

• Market numbers on micro-segments that are influencing the market
• Regulatory framework analysis and reimbursement scenario in developed and developing regions
• Current and future therapies’ potential
• Detailed country-level market share analysis, including the scrutiny of seven major markets

Besides these parameters, the study also encompasses the market growth drivers, opportunities, market restraining factors, competition mapping, segmental analysis, and a visual dashboard of all prominent products.

Our Research Team study highlights limitations with the current standard of care, low satisfaction with available therapies, robust pipeline products, rising uptake of narcolepsy awareness programs, improving diagnosis, and other factors. In addition, the continued significant investments by healthcare companies and government authorities to meet industry demand and the growing adoption of emerging therapies have been a catalyst for the progress of the global narcolepsy therapeutics market.

To gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include types of indications, therapeutics, and seven major markets, including the U.S., U.K., Germany, France, Spain, Italy, and Japan.

According to Sara Virmani, Senior Research Analyst, Our Research Team, “The global narcolepsy therapeutics market is in a dynamic stage. Low satisfaction with available therapies, improved recently marketed therapies, robust pipeline products, rising uptake of narcolepsy awareness programs, and improving diagnosis are contributing to significant growth of the market during the forecast period.. The continued substantial investments by healthcare companies and government authorities to meet industry demand and the growing adoption of emerging therapies are the major factors propelling the growth of the global narcolepsy therapeutics market.”

This report is a meticulous compilation of research on more than ten players in the market ecosystem. It draws upon insights from in-depth interviews with key opinion leaders of leading companies, market participants, and vendors. The report also comprises nine detailed company profiles, including several key players such as Jazz Pharmaceuticals PLC, Harmony Biosciences LLC, Avadel Pharmaceuticals, PLC, Axsome Therapeutics, Inc., Takeda Pharmaceutical Co Ltd, NLS Pharmaceutics AG, Suven Life Sciences Limited, Balance Therapeutics, and Sumitomo Pharma Co Ltd (Sunovion Pharmaceuticals Inc.).

Who should buy this report?

• Manufacturers of therapies in the field of sleep disorders
• Emerging companies in the field of narcolepsy to assess the market situation

Key Questions Answered in the Report:

• What are the major market drivers, challenges, and opportunities in the global narcolepsy therapeutics market?
• What are the key development strategies implemented by the major players to sustain in the competitive market?
• Which is the dominant therapeutic type developed by the leading and emerging players for narcolepsy?
• What are the key class of drugs that have been considered by leading players in the global narcolepsy therapeutics market?
• What are the most promising emerging and investigational therapies in narcolepsy?
• Which companies are anticipated to be highly disruptive in the future, and why?
• What are the reimbursement scenarios and the regulations for narcolepsy in seven aforementioned major markets?
• What are the treatment guidelines for narcolepsy in seven major markets?

Buy the report: Narcolepsy Therapeutics Market – A Global and Country Level Analysis: Focus on Therapeutics, Indication, Product, and Country – Analysis and Forecast, 2022-2032

The post CRI Report: Narcolepsy Therapeutics market was $915.2 MLN in 2021 first appeared on CRI Report.

The past few decades have witnessed a slow yet significant transformation in the healthcare robotics market. The beginning of the transformation can be traced back to the 19th century. Technological advancements in surgical systems and instruments have led to major breakthroughs and disruptive phases in the healthcare landscape across the world.

These breakthroughs began with the invention of the cystoscope in 1805. In addition, Antoine Jean Desormeaux developed the endoscope for the examination of the urinary tract and bladder.

The first laparoscopic procedure was performed in 1901. The inventions of the digital camera further aided in the visualization of internal tracts. Thus, the preference for minimally invasive surgeries (MISs) continued to grow over the decades, which led to the emergence of robotic-assisted surgeries.

The idea of robotic-assisted MIS procedures has been conceptualized and is being driven by the increasing need for using multiple tools through multiple access ports to support MISS. The first da Vinci system by Intuitive Surgical, Inc. received FDA approval for general laparoscopic surgery in XX.

As of 2018, the number of MIS procedures conducted annually was XX million, out of which XX million were robotic assisted.

“The global minimally invasive surgical systems market is to be valued at $27,882.8 million in 2020 and is anticipated to reach $55,716.7 million by the end of 2031.”

What are Prohibitive and Inhibitive Factors for Minimally Invasive Surgery Market Growth?

The introduction of new technologies, practices, and methodologies has a significant impact on the global minimally invasive surgical systems market. Constant competition among market players ensures that leading players in the market are innovative in terms of the usability of the systems as well as their features.

Several factors, such as the shift in preference for safer options than open surgeries, increasing preference for instruments with more dexterity, increasing affordability, and technological advances in the field of artificial intelligence (AI), haptics, and telesurgery are expected to play a key role in the growth of the market during the forecast period.

The preference for minimally invasive surgical (MIS) procedures is expected to increase during the next ten years, with robotic-assisted surgeries quickly gaining the market share. Practices involving MIS procedures encompass a wide range of fields, including radiology, radio intervention, cardiology (and interventionalist cardiology), and arthroscopy, among others.

Furthermore, the growing demand for MIS is likely to be propelled through offering a more connected interface, motion scaling, and tremor filtration.

The high cost of surgical robotic systems is one of the key factors restraining the growth in the adoption of surgical robotics technology. The adoption of surgical robotic systems incurs high installation and maintenance costs.

Additionally, the lack of skilled professionals is a challenge to the growth of this market. Among the factors contributing to adverse events during robotic-assisted surgeries, user errors and inadequately trained surgeons cumulatively account for XX% share of the adverse events.

Who are key players on Minimally Invasive Surgery market?

Boston Scientific Corporation

Boston Scientific Corporation is a developer and marketer of medical devices used in a wide range of interventional medical specialties. The company markets its products to approximately XX hospitals, clinics, and medical offices in more than XX countries worldwide.

The company has seven core businesses, namely, interventional cardiology, cardiac rhythm management, endoscopy, urology and pelvic health, peripheral interventions, neuromodulation, and electrophysiology.

Boston Scientific Corporation acquired EndoChoice in 2016, which then became part of its endoscopy business. Additionally, Boston Scientific Corporation acquired Emcision Ltd. Also in March 2018, Boston Scientifc Corporation acquired EMcision Limited, to expand its endoscopy portfolio to include the Habib EndoHPB probe and novel endoscopic bipolar radiofrequency devices.

Arthrex Inc.
Asensus Surgical, Inc.
Conmed Corporation
Fujifilm Holdings Corporation
Intuitive Surgical, Inc.
Karl Storz SE & Co. KG
Medtronic plc
Olympus Corporation
Hoya Corporation (Pentax Medical)
Siemens Healthineers AG
Smith & Nephew plc
Sony Corporation
Stryker Corporation
Zimmer Biomet Holdings, Inc.

What are key findings in Global Minimally Invasive Surgical Systems Market: Focus on Product Type, Application, End Users, 25 Countries’ Data, Patent Scenario, and Competitive Landscape – Analysis and Forecast, 2021-2031?

▪ The growing demand for robotic surgeries has given rise to several R&D programs focused on handheld robotics.
▪ Over the next decade, companies are likely to focus on enhancing their manufacturing capacities as demand for surgeries is likely to grow at an ever-faster rate.
▪ Miniaturization of surgical instruments, especially robotic instruments, is expected to be the next big thing in surgical robotics. However, the development of new mechanisms to support the infrastructure for the same is likely to be challenging, if not impossible, to achieve.
▪ There is an ongoing shift toward single-use endoscopes.

Request a sample for reviewing

[contact-form-7]

The post Medical Surgery – Shift from Open to Minimally Invasive, Drive Market Size Grow first appeared on CRI Report.

The global neoantigen cancer vaccine industry analysis projects the market to grow at a significant CAGR of 77.73% during the forecast period 2024-2031. The neoantigen cancer vaccine market is expected to generate $35.5 million in revenue in 2024, owing to the expected launch of the first neoantigen vaccine, DC vaccine in the market.

The neoantigen cancer vaccine market growth has been primarily attributed to major drivers in this market, such as rising prevalence of cancers, increasing adoption of personalized medicine to tailor patient’s treatment on an individual level, and significant external funding for executing research and development exercises. However, significant challenges are restraining the market growth. These challenges include the expected higher cost of personalized cancer vaccines, hurdles in clinical development, and payer uncertainty and outcome-based pricing.

Details in the report : Global Neoantigen Cancer Vaccine Market: Focus on Approach, Line of Therapy, Type, Application, Treatment Strategy, and Country-Wise Analysis – Analysis and Forecast, 2024-2031

What are Neoantigen cancer vaccines?

Neoantigen cancer vaccines are generally considered tumor-specific vaccines that are based on neoantigens being identified from an individual and further delivered via cell, protein, or nucleic acid-based platform with the utter aim of imparting a strong antitumor response. The neoantigen cancer vaccines are further segmented into personalized and off-the-shelf neovaccines based on the target neoantigen.

Neoantigen Cancer Vaccine in Cancer Immunotherapy

What are Growth Drivers of the Neoantigen cancer vaccines market?

• Increasing Global Prevalence of Cancer
• Increase in Adoption of Personalized Medicine to Tailor Patient’s Treatment on an Individual Level
• Significant External Funding for Executing Research and Development Exercise

What are Market Challenges for market players?

• Higher Cost of Personalized Cancer Vaccines
• Hurdles in Clinical Development and Optimization Process
• Uncertain Reimbursement Scenario
• Payer Uncertainty and Outcome-Based Pricing
• High Capital Requirement Hampering the Expansion of Global Reach

Who are top players in the Neoantigen cancer vaccines market?

Moderna Therapeutics

Website: www.modernatx.com

Moderna Therapeutics is a Cambridge, Massachusetts-based biotechnology company that specializes in messenger RNA (mRNA) based-drug discovery and development.

The company primarily caters to immuno-oncology, rare disease, and infectious disease therapy areas and currently holds three emerging neo-antigen vaccine candidates with respect to the global neoantigen cancer vaccine market.

It utilizes proprietary mRNA technology to develop novel mRNA-based neoantigen cancer vaccines, which are further delivered intramuscularly by lipid nanoparticles-based delivery vehicles.

Moderna’s expected stature as an emerging market player is primarily attributed to the portfolio of two personalized (mRNA-4650 and mRNA-4157) and one off-the-shelf neoantigen vaccine (mRNA-5671) in its pipeline. These vaccines, if approved, can generate phenomenal sales for the company.

F. Hoffmann-La Roche Ltd
AstraZeneca plc
Agenus
OSE Immunotherapeutics
Advaxis
Medigene
Neon Therapeutics
Genocea Biosciences
Immunovative Therapies
Gritstone Oncology
Nouscom
NantBioScience
Immunovaccine
BioLineRx
Geneos Therapeutics

How to get more details of the market?

Buy the report: Global Neoantigen Cancer Vaccine Market: Focus on Approach, Line of Therapy, Type, Application, Treatment Strategy, and Country-Wise Analysis – Analysis and Forecast, 2024-2031

Key Questions Answered in this Report:

• What are the major market drivers, challenges, and opportunities in the global neoantigen cancer vaccines market?
• What are the underlying structures resulting in emerging trends within the global neoantigen cancer vaccines market?
• What key development strategies are implemented by the major players in order to sustain in the competitive market?
• What are the key regulatory implications in developed and developing regions for neoantigen cancer vaccines?
• How each segment of the market is expected to grow during the forecast period 2024-2031, and what is the estimated revenue to be generated by each of the segments on the basis of:
o Product Type (Personalized and Off-the-Shelf),
o Type of Neovaccine (Nucleic Acid Vaccine, Peptide Vaccine, and Dendritic Cell-Based Vaccine)
o Line of Therapy (First Line, Second Line, and Later Lines)
o Region, including North America, Europe, Asia-Pacific and Middle East
• Who are the leading players with significant offerings to the global neoantigen cancer vaccines market? What is the expected market dominance for each of these leading players?
• Which companies are anticipated to be highly disruptive in the future and why?
• What are the current treatment gaps, and how neovaccines are expected to fill these gaps?
• What are the unmet needs in the global neoantigen cancer vaccine market?

The post Global Neoantigen cancer vaccines market expected to generate $35.5 million in revenue in 2024 first appeared on CRI Report.

The global dental software market is expected to register a CAGR of 10.50% during the forecast period and is expected to hit USD 4,331.67 million by 2027.

Dental Software Market Forecast till 2027

According to the WHO, oral health is of primary importance and has improved over the recent years due to increased awareness amongst people. Dental software refers to a computer technology utilized by dental professionals, dental laboratories, dental research and academic institutes, and forensic laboratories for the research, prevention, diagnosis, treatment, and investigation of oral health conditions.

The growth of the global dental software market is expected to be driven by key factors such as increasing adoption of digital dental radiography systems, advancements in dental technology, and a growing geriatric population. However, factors such as reluctance to adopt dental software are expected to restrict the market growth. In contrast, ongoing consolidation among private players offers lucrative opportunities for the global dental software market players.

Segment Analysis

The global dental software market is mainly segmented into type, deployment, and end user. On the basis of type, the dental software market has been sub-segmented into practice management software, patient communication software, treatment planning software, patient education software, dental imaging software, and others.

On the basis of deployment, the dental software market has been segmented into on-premise, web-based, and cloud-based. Based on end user, the global dental software market is segmented into dental clinics, hospitals, and others.

Regional Analysis

The global dental software market has been segmented on the basis of region into North America, Europe, Asia-Pacific, and the Rest of the World. The North American market is further divided into the US and Canada.

The European dental software market has been segmented into Germany, France, the UK, Italy, Spain, and the rest of Europe. The dental software market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World dental software market includes the Middle East, Africa, and Latin America.

In 2020, North America led the dental software market with a share of 38.61%, and this trend is expected to continue throughout the forecast period. This is due to the rapid adoption of dental software and associated digital technologies in dental laboratories in the recent past.

In 2019, three out of every five dental laboratories used CAD/CAM systems, over 57% of them used digital design software, and 28% of dental laboratories employed 3-D printers. The European region also held a significant share of the dental software market in 2020 due to factors like improving quality and increasing affordability of entry-level software solutions, technological advancements, and strict regulatory guidelines demanding improvement treatment quality.

Asia-Pacific is anticipated to register the highest growth rate over the forecast period from 2021 to 2027. This is due to factors such as the rising adoption of digital dental radiography systems and growth in the aging population.

According to United Nations Population Fund, formerly known as United Nations Fund for Population Activities (UNFPA), one in every four people in the region will be over 60 years by 2050. While the rest of the world region is expected to show slow growth due to the high investments, require to set up such systems.

Key Findings of the Study

• • The global dental software market is expected to reach USD 4,331.67 million by 2027 at a CAGR of 10.50% during the forecast period.

• • The North American region accounted for the largest share of the global market, which is majorly attributed to the rapid adoption of dental software and associated digital technologies in dental laboratories in this region.

• • Based on type, the practice management software segment accounted for the largest market share of 63.41% in 2020.

• • By deployment, the web-based segment dominated the market with a share of 55.48% in 2020.

• • On the basis of end user, the dental clinics segment dominated the market with a share of 61.97% in 2020.

• • Some of the key players operating in the dental software market are Abeldent Inc. (US), Dentimax LLC (US), Carestream Health, Inc. (US), Ace Dental Software (US), Datacon Dental Systems (US), Danaher (US), Henry Schein, Inc. (US), Imageworks Corporation (US), Open Dental Software Inc. (US), Planmeca OY (Finland), Dentsply Sirona (US), Consult-Pro (Canada), Patterson Dental (US), and Medicloud (Bulgaria).

[contact-form-7]

The post Global Dental Software Market 2027 first appeared on CRI Report.

The global blood grouping reagents market is expected to register a CAGR of 7.74% during the forecast period and is expected to hit USD 2,642.17 million by 2027.

Blood grouping reagents are solutions that can be used to determine ABO, Rhesus, Kell and MNS blood groups These classifications of human blood are all based on the presence or absence of certain antigens on the surface of red blood cells.

The growth of the global blood grouping reagents market is expected to be driven by increasing prevalence of chronic disorders, increasing spending in medical research. However, concern pertaining to efficiency and proficiency of test kits hamper the growth of this market.

Segment Analysis

The global blood grouping reagents market is mainly segmented into product, technique, and test type, end user. On the basis of product, the blood grouping reagents market has been bifurcated into consumables and instruments.

Instruments is further sub-segmented into fully automated and semi-automated. Technique products are further sub segmented into PCR-based and microarray techniques, assay-based techniques, massively parallel sequencing techniques, serology, and other techniques.

The serology segment is further sub-segmented into gel technique, erythrocytes magnetised technology (EMT), solid-phase red-cell adherence (SPRCA), glass slide, glass tube, cassette/kits, and others.

On the basis of test type, the blood grouping reagents market has been bifurcated into blood group and phenotypes, antibody screening, crossmatching tests, antibody identification, Coombs’s test, and antigen typing. Based on end user, the market is categorized into hospitals, blood banks, and clinical laboratories.

Regional Analysis

The global blood grouping reagents market has been segmented on the basis of region into North America, Europe, Asia-Pacific, and Rest of the World. The North America held the largest market share of 37.74% in 2020 and is anticipated to dominate the overall blood grouping reagents market during the forecast period.

The major factors driving North America blood grouping reagents market include the presence of major manufacturers, increasing prevalence of chronic diseases leading to the high demand for blood transfusion and organ transplant, technological advancements in the clinical segment, and increasing awareness among the population.

For instance, according to Health Resources & Services Administration, 39,000 transplants were performed in 2020. The key manufacturers are anticipated to launch new products, collaborate for optimization of the cash flow channel, and partially outsource the production process.

Europe holds the second largest market share due to the increasing number of medical device manufacturers, improving economies, high disposable income per individual, and increased healthcare spending are driving the growth of the market in this region. Moreover, the availability of high-end technologies in countries like Germany and growing funding from the various public as well as private sources to conduct advanced research are fostering market growth.

Asia-Pacific is the fastest-growing regional market for blood grouping reagents due to the increasing R&D funding by developing countries such as China and India for the development of the healthcare infrastructure. Various other factors that influence the markets growth include the growing incidence of traumatic injuries from accidents and trauma in the region.

Increasing demand for blood banking services, government initiatives and increasing public awareness about blood donation are driving the market’s growth in this region. Globally, road accidents are the tenth leading cause of death. India accounted for about 500,000 road accidents in 2019, one of the highest in the world, in which about 150,000 people die and another 300,000 became crippled.

In 2018, India had 467,044 reported road accidents, an increase of 0.5% from 464,910 in 2017, according to the road ministry’s data. Moreover, in 2018, 63,194 traffic accident fatalities were recorded by China’s National Bureau of Statistics. Many road accidents causing traumatic injuries are anticipated to increase the demand for blood grouping reagents in the region. 

The blood grouping reagents market in the Middle East & Africa is expected to witness steady growth due to the increasing number of companies and subsidiaries in the region offering treatment options.

The rest of the world, with fewer economic developments, accounted for the least market share in 2020 but is expected to grow with the increasing awareness among people and demand for better healthcare facilities in countries along with the rising disposable income. Moreover, improvement in regulatory structures in the region is further anticipated to drive the growth of the blood grouping reagents market.

Key Findings of the Study

• • The global blood grouping reagents market is expected to reach USD 2,642.17 million by 2027 at a CAGR of 7.74% during the forecast period.

• • Based on product, the consumables segment accounted for the largest market share of 75.55% in 2020.

• • On the basis of technique, the PCR-based and microarray technique segment dominated the market with a share of 17.92% in 2020.

• • By test type, the blood group and phenotype segment dominated the market with a share of 30.69% in 2020.

• • Based on end user, the hospitals segment dominated the market with a share of 58.33% in 2020.

• • The North America region accounted for the largest share of the global market, which is majorly attributed to the increasing prevalence of chronic diseases leading to the high demand for blood transfusion and organ transplant, technological advancements in the clinical segment, and increasing awareness among the population.

• • Some of the key players operating in the blood grouping reagents market are Merck KGaA (Germany),Bio-Rad Laboratories, Inc (US),Novacyt Group (France),Beckman Coulter, Inc (US), Haemokinesis Pty Ltd (Australia), MTC Med.
  • Produkte GmbH (Germany), DAY medical SA (Switzerland), Rapid Labs Ltd (UK), Ortho Clinical Diagnostics (US), Diagast SAS (France), Grifols SA (Spain), Immucor, Inc (US), Quotient Ltd (Switzerland), Yuvraj Biobiz Incubator India Pvt (India), Tulip Diagnostics (India), Aikang (China).

[contact-form-7]

The post Global Blood Grouping Reagents Market 2027 first appeared on CRI Report.

According to CRI analysis, the global 5G in healthcare market is expected to register a CAGR of ~ 74.5% from 2021 to 2028 and hold a value of USD ~ 4,200 million by 2028.

Factors driving the 5G market in healthcare, include quick transfer of huge imaging files, increasing adoption of telemedicine, remote monitoring that is both reliable & real-time and improving augmented reality, virtual reality, and spatial computing.

The high grade of virtual care, when combined with the availability of 5G and its huge potential, will revolutionize healthcare delivery to new heights.

Following the coronavirus pandemic, 5G Enhanced Mobile Broadband (eMBB) technology will offer remote support for high-quality healthcare while lowering patient exposure to contagion through few in-person visits to doctors and healthcare institutions. Patients who are unable to travel to their healthcare professionals will be able to visit them via telepresence equipment via 5G.

The key players are involved in new product launches, strategic agreements, funding, investments, and joint ventures to maintain their market positions. The key players in the 5G healthcare market have been implementing a variety of tactics to capitalize on growth prospects in the following years.

For example, ZTE (China) and Huawei (China) announced the establishment of 5G demonstration sites in June 2020. These sites are designed to give remote consultation in addition to outpatient and imaging diagnostics.

In addition, In October 2021, Verizon Business (US) launched a combination of customer-facing network, hardware, and intelligence offerings for Internet of Things (IoT) applications across industries that include manufacturing, healthcare, utilities, transportation, retail/supply chain, and public safety.

Regional Analysis

North America is expected to dominate the 5G in healthcare market, owing to growing 5G infrastructure investments, technological advancements, evolving healthcare models, and presence of major industry players across the region.

In addition, increased investments in R&D of new products by the government and private organizations have surged the level of competition among the market players. The prominent players are also involved in collaborations, partnerships, and geographic expansions, which contribute to market growth.

Europe is expected to account for the second-largest position in the 5G in healthacre market in 2021 due to significant investment by mobile operators to build 5G infrastructure across the region.

In addition, increasing demand for a low latency rate and the need to minimize downtime in remote robotic surgeries propels the growth of Europe 5G in healthcare market.. Technological advancements in Germany and UK aid in driving the 5G in healthcare market growth in the European region.

Asia-Pacific is anticipated to be the fastest-growing regional market during the forecast period due to increasing investment in healthcare infrastructure, rising number of geriatric population and growing awareness among the healthcare professionals about 5G technology uses in healthcare.

In addition, increasing modernization in healthcare infrastructure is creating new opportunities for industry players.

The growth of the 5G in healthcare market in the Rest of the World is attributed to the technological advancements in 5G technology solutions with the expansion of distribution channels throughout the region.

Segmentation

The global 5G in healthcare market has been segmented into hardware, services, and connectivity. By application, the market has been segregated into connected medical devices, remote patient monitoring, asset tracking for medical devices, AR/VR, conncetd ambulance and others. The connected medical devices segment is expected to hold a considerable share of the market in 2020 owing to the growing government initiative for promoting digital healthcare.

Based on end user, the global 5G in healthcare market has been classified as healthcare providers, healthcare payers and other end users. The healthcare providers segment held the largest market share in 2020, owing to the increasing application of the 5G technology solutions in healthcare.

Key players

Some of the key players in the global 5G in healthcare market are AT&T Inc. (US), Verizon (US), Ericsson (Sweden), T‑Mobile USA, Inc. (US), Cisco Systems, Inc. (US), Telit (UK), Orange S.A. (France), Telefónica, S.A. (Spain), SAMSUNG (South Korea), BT Group (UK), NEC Corporatioan (Japan), Qualcomm Technologies, Inc. (US), and NTT Docomo Inc. (Japan).

Small Cell 5G Network Market Overview of Key Strategies with Size & Share Analysis and Forecast 2019-2030

[contact-form-7]

The post 5G in Healthcare Market: Growing adoption of telemedicine and robotic surgery is augmenting the market growth at a healthy CAGR of ~ 74.5% during the forecast period of 2021 to 2028. : first appeared on CRI Report.

According to CRI analysis, the global 2D chromatography market is expected to register a CAGR of 7.4% from 2021 to 2027 and hold a value of USD 55.40 million by 2027.

The global 2D chromatography market is driven by several factors, such as rising R&D investments by biopharmaceutical & biotechnology companies for the development of new biologic drugs. In addition, the increasing applications of 2D chromatography in various industries such as forensic science, life science, food & beverage, and petrochemical further boost the growth of the market. Moreover, rising concerns about environmental protection and food safety are fueling the growth of the 2D chromatography market during the forecast period.

The key players are involved in product launches, strategic agreements, joint ventures, and acquisitions to augment their market positions. For instance, in February 2021, Thermo Fisher Scientific (US) launched vanquish 2D liquid chromatography system. This system provides a reliable platform for analyzing complex samples in-depth with the highest level of confidence, as well as peak identification and analysis for all types of analytes. Similarly, in May 2021, Scion Instruments (Netherlands) acquired the automated headspacer system HT3 and Versa from Teledyne Instruments, Inc. (US). With this acquisition, Scion Instruments will increase its presence in the analytical chromatography segment, which ultimately contributes to the 2D chromatography market growth.

Regional Analysis

North America is expected to dominate the 2D chromatography market, owing to rising research activities in pharmaceutical industries and higher government funding for research. Furthermore, the presence of major industry players across the region, such as Agilent Technologies, Inc. (US), Thermo Fisher Scientific (US), Danaher Corporation (US), LECO Corporation (US), and other players are dominating the global 2D chromatography market. Furthermore, the adoption of technologically advanced 2D chromatography systems is also fueling the growth of the market.

Europe is expected to hold a significant share in the 2D chromatography market due to the growing demand for 2D chromatography in the biopharmaceutical & petrochemical industry across the region. In addition, the presence of supportive regulatory systems is also expected to boost market growth.

Asia-Pacific is anticipated to be the fastest-growing regional market during the forecast period due to increasing investment in healthcare infrastructure, establishments of research organizations, and rising applications of 2D chromatography to assess purity and safety in pharmaceutical, agricultural, and food industries.

Furthermore, the growth of the market in the Rest of the World is attributed to the technological advancements in 2D chromatography systems and the growing biopharmaceutical & biotechnology sector in the region.

Segmentation

The global 2D chromatography market has been segmented into product, application, and end user. By product, the market has been segregated into 2D gas chromatography and 2D liquid chromatography.

2D gas chromatography is further segmented into 2D gas chromatography instruments, 2D gas chromatography consumables, and 2D gas chromatography accessories. 2D gas chromatography instruments is further segmented into systems, detectors, and other instruments. 2D gas chromatography consumables is further segmented into columns, vials, and other consumables. 2D liquid chromatography is segmented into 2D liquid chromatography instruments, 2D liquid chromatography consumables, and 2D liquid chromatography accessories. 2D liquid chromatography instruments is further segmented into systems, detectors, and other instruments. 2D liquid chromatography consumables is further segmented into columns, vials, and other consumables. The 2D gas chromatography segment held the majority share in 2020 due to the rapid growth in the petroleum industry, rising environmental pollution, and food safety concerns.

By application, the market has been segregated into life science research, environmental analysis, food & beverage testing, petrochemical & natural gas analysis, and others. The life science research segment is expected to hold a considerable share of the market in 2020. This can be attributed to the increasing focus on biotechnology, genomics, proteomics, bioinformatics, pharmaceutical, and biomedical research will augment the market growth in the assessed period.

Based on end user, the global 2D chromatography market has been classified as biotechnology & pharmaceutical industries, hospitals & clinics, and others. Biotechnology & pharmaceutical industries held the largest segment share in 2020, owing to the rapidly growing biotechnology & pharmaceutical industry and rising focus on drug development, boosting the market growth.

Key Players

Some of the key players in the global 2D chromatography market are Agilent Technologies, Inc. (US), LECO Corporation (US), Waters Corporation (US), Shimadzu Corporation (Japan), Restek Corporation (US), Sepsolve Analytical Ltd (UK), Merck KGaA (Germany), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), and Thermo Fisher Scientific (US).

Global Life Science Reagents Market 2029

[contact-form-7]

The post 2D Chromatography Market: Rising life science research and growing applications of 2D chromatography is augmenting the market growth at a healthy CAGR of 7.4% during the forecast period of 2021 to 2027 first appeared on CRI Report.